<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）于周四发布了其财报。该公司报告本季度每股收益为 1.14 美元，低于分析师一致预期的 1.16 美元，差距为 0.02 美元，FiscalAI 报道。该季度的收入为 2.8344 亿美元，而分析师预期为 2.8693 亿美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。在去年同期，该公司的每股收益为 1.22 美元。该公司的收入同比下降了 2.4%。Prestige Consumer Healthcare 更新了其 2026 财年的指引，预计每股收益为 4.540-4.540 美元。</p>
<p>以下是 Prestige Consumer Healthcare 电话会议的关键要点：</p>
<ul>
<li><strong>Clear Eyes</strong> 的供应正在逐步改善，管理层预计在收购 <strong>Pillar Five</strong> 并安装新的 <strong>高速生产线</strong> 后，第四季度及 2026 年将进一步取得进展，这将使内部生产、SKU 扩展和重新启动市场支持成为可能。</li>
<li>第三季度收入为 <strong>2.834 亿美元</strong>，同比下降约 2.4%（剔除汇率影响后为 2.2%），调整后的每股收益降至 <strong>1.14 美元</strong>，主要受限于 Clear Eyes 的供应瓶颈以及止痛药和感冒药类别的疲软。</li>
<li>强劲的现金生成（截至目前自由现金流为 <strong>2.088 亿美元</strong>，增长 12.9%）支撑了严格的资本配置：公司完成了约 <strong>1.1 亿美元</strong> 的 Pillar Five 交易，并回购了超过 <strong>1.5 亿美元</strong> 的股票（约占流通股的 5%），同时保持了约 <strong>10 亿美元</strong> 的净债务（杠杆比率约为 2.6 倍）。</li>
<li>管理层将 2026 财年的指引缩小至约 <strong>11 亿美元</strong> 的收入和约 <strong>4.54 美元</strong> 的调整后每股收益，预计第四季度调整后的毛利率约为 57%，销售和市场费用占销售额的 14% 以下，全年一般和行政费用占销售额的 10% 以上，并将在 5 月的电话会议上提供更多 2027 年的细节。</li>
</ul>
<h2>Prestige Consumer Healthcare 股票下跌 3.3%</h2>
<p>周四，NYSE:PBH 的股票交易下跌 2.18 美元，跌至 64.85 美元。该公司交易了 452,612 股，较其平均交易量 377,745 股有所增加。该公司的市值为 31.2 亿美元，市盈率为 16.14，市盈增长比率为 2.02，贝塔值为 0.43。该公司的债务与股本比率为 0.55，流动比率为 3.70，速动比率为 2.51。Prestige Consumer Healthcare 的 12 个月低点为 57.25 美元，12 个月高点为 90.04 美元。该公司的 50 日移动平均价格为 62.94 美元，200 日移动平均价格为 64.12 美元。</p>
<h2>分析师评级变动</h2>
<p>几位研究分析师对 PBH 股票发表了看法。Jefferies Financial Group 将 Prestige Consumer Healthcare 的目标价从 70.00 美元下调至 66.00 美元，并在 1 月 30 日的研究报告中对该股票给予 “持有” 评级。Zacks Research 在 11 月 10 日的研究报告中将 Prestige Consumer Healthcare 的评级从 “强烈卖出” 上调至 “持有”。Oppenheimer 在 10 月 21 日的报告中将 Prestige Consumer Healthcare 的目标价从 82.00 美元下调至 72.00 美元，并对该公司给予 “跑赢大盘” 的评级。Canaccord Genuity Group 在 11 月 7 日的研究报告中将 Prestige Consumer Healthcare 的目标价从 100.00 美元下调至 88.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Prestige Consumer Healthcare 的 “持有（c）” 评级。四位股票研究分析师对该股票给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 84.50 美元。</p>
<p><strong>阅读我们对 PBH 的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在其他 Prestige Consumer Healthcare 的新闻中，副总裁 Jeffrey Zerillo 于 11 月 28 日星期五出售了 719 股该公司的股票。股票以 60.00 美元的平均价格出售，总交易额为 43,140.00 美元。出售完成后，该副总裁直接持有公司 42,329 股股票，价值约为 2,539,740 美元。此交易代表其持股减少了 1.67%。该出售在与 SEC 的法律文件中披露，文件可通过此超链接获取。1.40% 的股票由内部人士持有。</p>
<h2>对 Prestige Consumer Healthcare 的对冲基金看法</h2>
<p>几家大型投资者最近调整了对该公司的持股。Danske Bank A S 在第三季度购买了 Prestige Consumer Healthcare 的新股份，价值 37,000 美元。Brown Brothers Harriman &amp; Co.在第三季度购买了 Prestige Consumer Healthcare 的新股份，价值 44,000 美元。Geneos Wealth Management Inc.在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.现在持有该公司 559 股股票，价值 48,000 美元，此前在上个季度购买了额外的 269 股。CIBC Private Wealth Group LLC 在第三季度将其在 Prestige Consumer Healthcare 的持股增加了 142.8%。CIBC Private Wealth Group LLC 现在持有该公司 1,100 股股票，价值 69,000 美元，此前在此期间购买了额外的 647 股。最后，怀俄明州州政府在第二季度购买了 Prestige Consumer Healthcare 的新股份，价值约 97,000 美元。对冲基金和其他机构投资者持有该公司 99.95% 的股票。</p>
<h2>关于 Prestige Consumer Healthcare</h2>
<p>（获取免费报告）</p>
<p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品的制造商和营销商。该公司专注于开发、收购和商业化多样化的非处方药物组合，以满足消费者的常见健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
<p>Prestige 旗下的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸药）、Monistat（女性健康）、BC Powder（止痛药）、Little Remedies（儿童感冒和胀气缓解）以及 TheraTears（干眼症治疗）。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Prestige Consumer Healthcare 更好的股票</li>
<li>黄金市场崩溃的那一天</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>你的银行账户不再安全</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Prestige Consumer Healthcare 吗？</h2>
<p>在考虑 Prestige Consumer Healthcare 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Prestige Consumer Healthcare 并不在名单上。</p>
<p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

普雷斯蒂奇

<p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH）公布了第三季度财报，每股收益为 1.14 美元，低于预期 0.02 美元。收入为 2.8344 亿美元，低于预期的 2.8693 亿美元，同比下降 2.4%。公司更新了 2026 财年的指引，预计每股收益约为 4.54 美元。股价下跌 3.3%，至 64.85 美元。分析师的评级不一，整体为适度买入，平均目标价为 84.50 美元。内部人士持有 1.40% 的股份，最近的交易包括副总裁 Jeffrey Zerillo 出售价值 43,140 美元的股票</p>

<p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) issued its earnings results on Thursday. The company reported $1.14 EPS for the quarter, missing analysts' consensus estimates of $1.16 by ($0.02), FiscalAI reports. The business had revenue of $283.44 million during the quarter, compared to analysts' expectations of $286.93 million. Prestige Consumer Healthcare had a net margin of 18.09% and a return on equity of 12.43%. During the same period in the prior year, the business posted $1.22 EPS. The business's revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare updated its FY 2026 guidance to 4.540-4.540 EPS.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（纽约证券交易所代码：PBH - 获取免费报告）于周四发布了其财报。该公司报告本季度每股收益为 1.14 美元，低于分析师一致预期的 1.16 美元，差距为 0.02 美元，FiscalAI 报道。该季度的收入为 2.8344 亿美元，而分析师预期为 2.8693 亿美元。Prestige Consumer Healthcare 的净利润率为 18.09%，股本回报率为 12.43%。在去年同期，该公司的每股收益为 1.22 美元。该公司的收入同比下降了 2.4%。Prestige Consumer Healthcare 更新了其 2026 财年的指引，预计每股收益为 4.540-4.540 美元。</p>
</div><p>Here are the key takeaways from Prestige Consumer Healthcare's conference call:</p>
<div class="lb-trans"><p>以下是 Prestige Consumer Healthcare 电话会议的关键要点：</p>
</div><ul>
<li><strong>Clear Eyes</strong> supply is improving sequentially and management expects further progress in Q4 and through calendar 2026 after acquiring <strong>Pillar Five</strong> and installing a new <strong>high-speed line</strong>, which should enable internal production, SKU expansion and renewed marketing support.</li>
<li>Q3 revenue of <strong>$283.4 million</strong> declined ~2.4% YoY (2.2% ex-FX) and adjusted EPS slipped to <strong>$1.14</strong>, driven primarily by Clear Eyes supply constraints and category softness in analgesics and cough &amp; cold.</li>
<li>Strong cash generation (YTD free cash flow of <strong>$208.8 million</strong>, +12.9%) underpins disciplined capital allocation: the company closed the ~ <strong>$110 million</strong> Pillar Five deal and repurchased &gt; <strong>$150 million</strong> of shares (~5% of outstanding), while maintaining net debt of ~ <strong>$1 billion</strong> (leverage ~2.6x).</li>
<li>Management narrowed fiscal 2026 guidance to about <strong>$1.1 billion</strong> in revenue and ~ <strong>$4.54</strong> adjusted EPS, expects Q4 adjusted gross margin ~57%, A&amp;M just under 14% of sales and full-year G&amp;A just over 10%, and will provide more 2027 detail on the May call.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Clear Eyes</strong> 的供应正在逐步改善，管理层预计在收购 <strong>Pillar Five</strong> 并安装新的 <strong>高速生产线</strong> 后，第四季度及 2026 年将进一步取得进展，这将使内部生产、SKU 扩展和重新启动市场支持成为可能。</li>
<li>第三季度收入为 <strong>2.834 亿美元</strong>，同比下降约 2.4%（剔除汇率影响后为 2.2%），调整后的每股收益降至 <strong>1.14 美元</strong>，主要受限于 Clear Eyes 的供应瓶颈以及止痛药和感冒药类别的疲软。</li>
<li>强劲的现金生成（截至目前自由现金流为 <strong>2.088 亿美元</strong>，增长 12.9%）支撑了严格的资本配置：公司完成了约 <strong>1.1 亿美元</strong> 的 Pillar Five 交易，并回购了超过 <strong>1.5 亿美元</strong> 的股票（约占流通股的 5%），同时保持了约 <strong>10 亿美元</strong> 的净债务（杠杆比率约为 2.6 倍）。</li>
<li>管理层将 2026 财年的指引缩小至约 <strong>11 亿美元</strong> 的收入和约 <strong>4.54 美元</strong> 的调整后每股收益，预计第四季度调整后的毛利率约为 57%，销售和市场费用占销售额的 14% 以下，全年一般和行政费用占销售额的 10% 以上，并将在 5 月的电话会议上提供更多 2027 年的细节。</li>
</ul>
</div><h2>Prestige Consumer Healthcare Stock Down 3.3%</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 股票下跌 3.3%</h2>
</div><p>Shares of NYSE:PBH traded down $2.18 during trading on Thursday, hitting $64.85. 452,612 shares of the company were exchanged, compared to its average volume of 377,745. The stock has a market capitalization of $3.12 billion, a P/E ratio of 16.14, a PEG ratio of 2.02 and a beta of 0.43. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.70 and a quick ratio of 2.51. Prestige Consumer Healthcare has a 12-month low of $57.25 and a 12-month high of $90.04. The firm's 50 day moving average price is $62.94 and its 200-day moving average price is $64.12.</p>
<div class="lb-trans"><p>周四，NYSE:PBH 的股票交易下跌 2.18 美元，跌至 64.85 美元。该公司交易了 452,612 股，较其平均交易量 377,745 股有所增加。该公司的市值为 31.2 亿美元，市盈率为 16.14，市盈增长比率为 2.02，贝塔值为 0.43。该公司的债务与股本比率为 0.55，流动比率为 3.70，速动比率为 2.51。Prestige Consumer Healthcare 的 12 个月低点为 57.25 美元，12 个月高点为 90.04 美元。该公司的 50 日移动平均价格为 62.94 美元，200 日移动平均价格为 64.12 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several research analysts have weighed in on PBH shares. Jefferies Financial Group cut their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a &#34;hold&#34; rating on the stock in a research report on Friday, January 30th. Zacks Research raised shares of Prestige Consumer Healthcare from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday, November 10th. Oppenheimer reduced their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an &#34;outperform&#34; rating for the company in a report on Tuesday, October 21st. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $84.50.</p>
<div class="lb-trans"><p>几位研究分析师对 PBH 股票发表了看法。Jefferies Financial Group 将 Prestige Consumer Healthcare 的目标价从 70.00 美元下调至 66.00 美元，并在 1 月 30 日的研究报告中对该股票给予 “持有” 评级。Zacks Research 在 11 月 10 日的研究报告中将 Prestige Consumer Healthcare 的评级从 “强烈卖出” 上调至 “持有”。Oppenheimer 在 10 月 21 日的报告中将 Prestige Consumer Healthcare 的目标价从 82.00 美元下调至 72.00 美元，并对该公司给予 “跑赢大盘” 的评级。Canaccord Genuity Group 在 11 月 7 日的研究报告中将 Prestige Consumer Healthcare 的目标价从 100.00 美元下调至 88.00 美元，并对该股票给予 “买入” 评级。最后，Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Prestige Consumer Healthcare 的 “持有（c）” 评级。四位股票研究分析师对该股票给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，平均目标价为 84.50 美元。</p>
</div><p><strong>Read Our Latest Analysis on PBH</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 PBH 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 719 shares of the firm's stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the sale, the vice president directly owned 42,329 shares in the company, valued at approximately $2,539,740. This trade represents a 1.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.40% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Prestige Consumer Healthcare 的新闻中，副总裁 Jeffrey Zerillo 于 11 月 28 日星期五出售了 719 股该公司的股票。股票以 60.00 美元的平均价格出售，总交易额为 43,140.00 美元。出售完成后，该副总裁直接持有公司 42,329 股股票，价值约为 2,539,740 美元。此交易代表其持股减少了 1.67%。该出售在与 SEC 的法律文件中披露，文件可通过此超链接获取。1.40% 的股票由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>对 Prestige Consumer Healthcare 的对冲基金看法</h2>
</div><p>Several large investors have recently modified their holdings of the business. Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare in the third quarter worth $37,000. Brown Brothers Harriman &amp; Co. purchased a new stake in Prestige Consumer Healthcare in the third quarter valued at $44,000. Geneos Wealth Management Inc. increased its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after purchasing an additional 269 shares in the last quarter. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 142.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company's stock worth $69,000 after buying an additional 647 shares during the period. Finally, State of Wyoming bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter worth about $97,000. Hedge funds and other institutional investors own 99.95% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对该公司的持股。Danske Bank A S 在第三季度购买了 Prestige Consumer Healthcare 的新股份，价值 37,000 美元。Brown Brothers Harriman &amp; Co.在第三季度购买了 Prestige Consumer Healthcare 的新股份，价值 44,000 美元。Geneos Wealth Management Inc.在第一季度将其在 Prestige Consumer Healthcare 的持股增加了 92.8%。Geneos Wealth Management Inc.现在持有该公司 559 股股票，价值 48,000 美元，此前在上个季度购买了额外的 269 股。CIBC Private Wealth Group LLC 在第三季度将其在 Prestige Consumer Healthcare 的持股增加了 142.8%。CIBC Private Wealth Group LLC 现在持有该公司 1,100 股股票，价值 69,000 美元，此前在此期间购买了额外的 647 股。最后，怀俄明州州政府在第二季度购买了 Prestige Consumer Healthcare 的新股份，价值约 97,000 美元。对冲基金和其他机构投资者持有该公司 99.95% 的股票。</p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>关于 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare, Inc 是一家领先的品牌非处方（OTC）医疗产品的制造商和营销商。该公司专注于开发、收购和商业化多样化的非处方药物组合，以满足消费者的常见健康需求，包括疼痛缓解、感冒和咳嗽、消化健康、眼部护理、皮肤护理和女性健康。</p>
</div><p>Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).</p>
<div class="lb-trans"><p>Prestige 旗下的主要品牌包括 Clear Eyes（眼部健康）、Carmex（唇部护理）、Chloraseptic（喉咙痛缓解）、Dramamine（晕动病）、Rolaids（抗酸药）、Monistat（女性健康）、BC Powder（止痛药）、Little Remedies（儿童感冒和胀气缓解）以及 TheraTears（干眼症治疗）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>The day the gold market broke</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Prestige Consumer Healthcare 更好的股票</li>
<li>黄金市场崩溃的那一天</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>你的银行账户不再安全</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Prestige Consumer Healthcare 吗？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Prestige Consumer Healthcare 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Prestige Consumer Healthcare 并不在名单上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prestige Consumer Healthcare 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

普雷斯蒂奇消费保健公司（NYSE:PBH）发布了财报，每股收益比预期低 0.02 美元